[15] [16] Patients should be advised to seek medical attention for symptoms such as right upper quadrant pain, fever, or jaundice
Butyrate producers are also sensitive to iron availability, while butyrate production is enhanced at high iron concentrations (65, 66)
In arteries, more TMAO leads to an increased deposition of cholesterol from the blood, which can lead to atherosclerosis
launch expected April Coordinated global commercialization My takeaway 1 Obesity drugs = new pharma battleground This is now a head-to-head innovation race, not just market expansion 2 Small efficacy differences = huge market impact Even a few percentage points shift prescribing behavior + billions in revenue 3 Lifecycle management is critical Higher doses, new pens, expanded indications = defending blockbuster franchises 4 Broader implication Expect continued competition across: GLP-1 / incretin space Combination therapies Next-gen metabolic drugs #Pharma #Obesity #GLP1 #NovoNordisk #EliLilly #DrugDevelopment #HealthcareInnovation To view or add a comment, sign in Eli Lilly and Company's orforglipron target raised by Wolfe analyst amid strong market potential orforglipron Eli Lilly obesity Wolfe analyst has raised the price target for Eli Lilly from $1250 to $1325, citing strong long-term demand for its experimental oral obesity drug, orforglipron
While GLP-1 therapies are known for achieving greater weight loss compared to controls, they often come with side effects like nausea, vomiting, and dizziness, which lead many patients to stop treatment prematurely
,
